동반진단 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 제품 및 서비스별, 기술별, 질환 적응증별, 용도별, 최종사용자별, 지역별 부문, 경쟁(2020-2030년)
Companion Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product and Services, By Technology, By Disease Indication, By Application, By End User, By Region and Competition, 2020-2030F
상품코드:1796829
리서치사:TechSci Research
발행일:2025년 08월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
동반진단 세계 시장 규모는 2024년에 61억 7,000만 달러로 평가되었습니다. 예측 기간 중 연평균 복합 성장률(CAGR)은 11.94%로, 2030년에는 121억 4,000만 달러에 이를 것으로 예측됩니다.
동반진단제는 치료제와 함께 사용되는 의료기기로, 특정 개인에 대한 약물의 영향과 적합성을 평가하기 위해 사용됩니다. 이러한 진단약은 치료제와 함께 개발되며, 그 특성에 따라 치료제에 반응하는 환자군과 치료제에 적합하지 않은 환자군을 식별합니다. 의료 전문가는 이 장치를 사용하여 환자에 대한 특정 치료의 효과를 평가할 수 있습니다. 2020년, 로슈는 폐암 치료에서 EGFR 티로신 키나아제 억제제의 적절한 사용을 판단하는 데 도움을 주는 코바스 EGFR 돌연변이 검사 v2 동반 진단에 대한 FDA 승인을 획득했습니다. 동반진단(CDx)은 치료제와 공동 개발된 임상 검사로, 치료제에 반응하는 환자, 반응하지 않는 환자를 식별합니다. CDx를 통해 해당 약물로 치료가 가능한 환자군과 불가능한 환자군을 구분할 수 있습니다. CDx는 치료제의 혜택, 부작용, 관련 위험을 평가하고 환자의 안전을 보장하는 데 도움이 됩니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
61억 7,000만 달러
시장 규모 : 2030년
121억 4,000만 달러
CAGR : 2025년-2030년
11.94%
급성장 부문
종양학
최대 시장
북미
세계 동반진단제 시장은 맞춤형 치료에 대한 환자 수요 증가, 맞춤형 약물의 적용 확대, 만성질환 유병률 증가, 약물 관련 알레르기 발생률 증가 등의 요인에 의해 주도되고 있습니다. 이러한 요인들은 맞춤형 CDx의 개발에 기여하고 시장 성장을 가속합니다. 또한, CDx 검사는 비용 효율성, 높은 민감도, 단시간에 빠르고 정확한 결과 등의 이점을 제공하여 동반진단제 시장의 성장을 더욱 촉진하고 있습니다.
주요 시장 성장 촉진요인
NGS 기반 기술에 대한 수요 증가
주요 시장 이슈
동반진단 기술에 대한 인식 부족과 높은 비용
주요 시장 동향
프로모션 활동의 중요성 증대
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 동반진단 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
제품 및 서비스별(키트 및 시약, 어세이, 소프트웨어 및 서비스)
기술별(PCR, NGS, In-Situ Hybridization, 면역조직화학 등)
질환 적응증별(종양학, 신경학, 심장학, 감염증 등)
용도별(체외진단, Drug Discovery, 기타)
최종사용자별(제약 기업 및 바이오테크놀러지 기업, 연구기관, 수탁 연구기관 등)
지역별
기업별(2024년)
시장 맵
제6장 북미의 동반진단 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 동반진단 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
영국
이탈리아
프랑스
스페인
제8장 아시아태평양의 동반진단 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 동반진단 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 동반진단 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트(UAE)
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
인수합병(M&A)
제품 출시
제13장 세계의 동반진단 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Abbott Laboratories Inc.
Agilent Technologies Inc.
F.Hoffmann-La Roche Ltd
Biomerieux SA
Qiagen NV
Siemens Healthcare
Thermo Fisher Scientific Inc.
Danaher Corporation(Beckman Coulter Inc.)
Myriad Genetics Inc.
Illumina Inc.
제16장 전략적 제안
제17장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
Global Companion Diagnostic Market was valued at USD 6.17 Billion in 2024 and is expected to reach USD 12.14 Billion by 2030 with a CAGR of 11.94% during the forecast period. Companion diagnostics are medical devices used in conjunction with therapeutic drugs to assess the impact and suitability of drugs for specific individuals. These diagnostics are developed alongside drugs to identify patient groups that respond to or are not suitable for the therapy based on their characteristics. Healthcare professionals utilize this device to evaluate the effectiveness of a particular treatment for a patient. In 2020, Roche obtained FDA approval for the Cobas EGFR Mutation Test v2 companion diagnostic, which assists in determining the appropriate use of EGFR tyrosine kinase inhibitors for lung cancer treatment. Companion Diagnostic (CDx) is a clinical test co-developed with a therapeutic drug to identify patients who will respond or not respond to the drug. It enables the identification of patient groups that can or cannot be treated with the corresponding drug. CDx helps practitioners evaluate the benefits, side effects, and associated risks of therapeutic drugs, ensuring patient safety.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 6.17 Billion
Market Size 2030
USD 12.14 Billion
CAGR 2025-2030
11.94%
Fastest Growing Segment
Oncology
Largest Market
North America
The global Companion Diagnostics Market is driven by factors such as increasing patient demand for tailored therapy, expanded applications of personalized medications, higher prevalence of chronic diseases, and growing incidence of medication-related allergies. These factors contribute to the development of customized CDx, promoting market growth. Additionally, CDx tests offer advantages such as cost-effectiveness, high sensitivity, and rapid and accurate results within shorter time frames, further fueling the growth of the Companion Diagnostics Market.
Key Market Drivers
Increasing Demand for NGS-Based Technology
The growing demand for next-generation sequencing (NGS) technology, with its exceptional capability to identify rare variants, plays a critical role in the continued success and wider distribution of companion diagnostics solutions in the companion diagnostics market. By utilizing NGS panels, a single test has the potential to aid in the treatment of numerous types of cancers, offering a more comprehensive approach to personalized medicine.
For instance, in July 2022, Almac Diagnostic forged a strategic partnership with AstraZeneca, a leading pharmaceutical company, to collaboratively develop and commercialize multiple companion diagnostic (CDx) products. These innovative CDx solutions will be based on cutting-edge NGS (next-generation sequencing) and qPCR-based (quantitative polymerase chain reaction) technologies, further advancing the field of precision medicine and enhancing patient care. Through this collaboration, Almac Diagnostic and AstraZeneca aim to improve the accuracy and effectiveness of diagnostics, enabling targeted therapies and personalized treatment plans for patients. This partnership demonstrates the commitment of both companies to drive innovation in the field of companion diagnostics and contribute to the advancement of precision medicine.
By leveraging the power of NGS and qPCR technologies, Almac Diagnostic and AstraZeneca envision a future where companion diagnostics play a pivotal role in guiding treatment decisions and improving patient outcomes across various therapeutic areas. This collaboration represents a significant step forward in the development of advanced diagnostic solutions that will revolutionize the way diseases are diagnosed and treated. With the combination of cutting-edge technologies and strategic partnerships, the field of precision medicine is poised to make significant strides in improving patient care and transforming healthcare on a global scale.
Key Market Challenges
Lack of Awareness and High Cost of Companion Diagnostics Techniques
While immunotherapy has shown significant promise in the treatment of cancer, its high cost has limited widespread patient access. As a result, physicians may opt to combine treatments, which can extend the duration of treatment from five months to over three years. With longer treatment duration comes a greater financial burden, as the cost of personalized immunotherapies is also substantial. In fact, the cost of cancer immunotherapies can far exceed that of other treatment options such as chemotherapy or radiation therapy. Consequently, the high cost of immuno-oncology treatments is believed to impede the growth of the companion diagnostics market. This financial barrier highlights the need for continued research and innovation to develop more affordable and accessible immunotherapies for cancer patients.
Key Market Trends
Growing Importance of Promotional Activities
The increasing significance of promotional activities represents a key trend in the companion diagnostics market. Companion diagnostics, due to their specificity in being applicable only to particular drugs, are not as extensively marketed as other available test kits and devices in the market. Therefore, it is crucial to give greater attention to improving the distribution network and enhancing the availability of products to end users. In terms of advertising sources, internet channels and search engines are among the most vital, considering their higher visibility and the limited return on investment and visibility of other media.
Furthermore, besides boosting sales, emphasis is placed on product functionality, accuracy, and vendors' after-sales services, while marketing communication takes a back seat. Limited promotion activities pose challenges in reaching the target market and understanding a company's competitive position. To attract customers to a company website, the publication of multiple blogs and newsletters can be beneficial. This approach allows businesses to sustain their marketing campaigns over an extended period and attract repeat visitors. As the market continues to witness product enhancements, vendors are increasingly recognizing the importance of promotional activities, and this trend is expected to gain momentum, thereby supporting the growth of the global companion diagnostics market throughout the forecast period.
Key Market Players
Abbott Laboratories Inc.
Agilent Technologies Inc.
F.Hoffmann-La Roche Ltd
Biomerieux SA
Qiagen NV
Siemens Healthcare
Thermo Fisher Scientific Inc.
Danaher Corporation (Beckman Coulter Inc.)
Myriad Genetics Inc.
Illumina Inc.
Report Scope:
In this report, the Global Companion Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Companion Diagnostic Market, By Product and Services:
Kits and Reagents
Assays
Software
Services
Companion Diagnostic Market, By Technology:
PCR
NGS
In-Situ Hybridization
Immunohistochemistry
Others
Companion Diagnostic Market, By Disease Indication:
Oncology
Neurology
Cardiology
Infectious Diseases
Others
Companion Diagnostic Market, By Application:
In-Vitro Diagnostics
Drug Discovery
Others
Companion Diagnostic Market, By End User:
Pharmaceutical & Biotechnology Companies
Research Laboratories
Contract Research Organization Others
Companion Diagnostic Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Companion Diagnostic Market.
Available Customizations:
Global Companion Diagnostic market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Companion Diagnostic Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product and Services (Kits and Reagents, Assays, Software, and Services)
5.2.2. By Technology (PCR, NGS, In-Situ Hybridization, Immunohistochemistry, and Others)
5.2.3. By Disease Indication (Oncology, Neurology, Cardiology, Infectious Diseases, and Others)
5.2.4. By Application (In-Vitro Diagnostics, Drug Discovery, and Others)
5.2.5. By End User (Pharmaceutical & Biotechnology Companies, Research Laboratories, Contract Research Organization, and Others)
5.2.6. By Region
5.2.7. By Company (2024)
5.3. Market Map
6. North America Companion Diagnostic Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product and Services
6.2.2. By Technology
6.2.3. By Disease Indication
6.2.4. By Application
6.2.5. By End User
6.2.6. By Country
6.3. North America: Country Analysis
6.3.1. United States Companion Diagnostic Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product and Services
6.3.1.2.2. By Technology
6.3.1.2.3. By Disease Indication
6.3.1.2.4. By Application
6.3.1.2.5. By End User
6.3.2. Canada Companion Diagnostic Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product and Services
6.3.2.2.2. By Technology
6.3.2.2.3. By Disease Indication
6.3.2.2.4. By Application
6.3.2.2.5. By End User
6.3.3. Mexico Companion Diagnostic Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product and Services
6.3.3.2.2. By Technology
6.3.3.2.3. By Disease Indication
6.3.3.2.4. By Application
6.3.3.2.5. By End User
7. Europe Companion Diagnostic Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product and Services
7.2.2. By Technology
7.2.3. By Disease Indication
7.2.4. By Application
7.2.5. By End User
7.2.6. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Companion Diagnostic Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product and Services
7.3.1.2.2. By Technology
7.3.1.2.3. By Disease Indication
7.3.1.2.4. By Application
7.3.1.2.5. By End User
7.3.2. United Kingdom Companion Diagnostic Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product and Services
7.3.2.2.2. By Technology
7.3.2.2.3. By Disease Indication
7.3.2.2.4. By Application
7.3.2.2.5. By End User
7.3.3. Italy Companion Diagnostic Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product and Services
7.3.3.2.2. By Technology
7.3.3.2.3. By Disease Indication
7.3.3.2.4. By Application
7.3.3.2.5. By End User
7.3.4. France Companion Diagnostic Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product and Services
7.3.4.2.2. By Technology
7.3.4.2.3. By Disease Indication
7.3.4.2.4. By Application
7.3.4.2.5. By End User
7.3.5. Spain Companion Diagnostic Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product and Services
7.3.5.2.2. By Technology
7.3.5.2.3. By Disease Indication
7.3.5.2.4. By Application
7.3.5.2.5. By End User
8. Asia-Pacific Companion Diagnostic Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product and Services
8.2.2. By Technology
8.2.3. By Disease Indication
8.2.4. By Application
8.2.5. By End User
8.2.6. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Companion Diagnostic Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product and Services
8.3.1.2.2. By Technology
8.3.1.2.3. By Disease Indication
8.3.1.2.4. By Application
8.3.1.2.5. By End User
8.3.2. India Companion Diagnostic Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product and Services
8.3.2.2.2. By Technology
8.3.2.2.3. By Disease Indication
8.3.2.2.4. By Application
8.3.2.2.5. By End User
8.3.3. Japan Companion Diagnostic Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product and Services
8.3.3.2.2. By Technology
8.3.3.2.3. By Disease Indication
8.3.3.2.4. By Application
8.3.3.2.5. By End User
8.3.4. South Korea Companion Diagnostic Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product and Services
8.3.4.2.2. By Technology
8.3.4.2.3. By Disease Indication
8.3.4.2.4. By Application
8.3.4.2.5. By End User
8.3.5. Australia Companion Diagnostic Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product and Services
8.3.5.2.2. By Technology
8.3.5.2.3. By Disease Indication
8.3.5.2.4. By Application
8.3.5.2.5. By End User
9. South America Companion Diagnostic Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product and Services
9.2.2. By Technology
9.2.3. By Disease Indication
9.2.4. By Application
9.2.5. By End User
9.2.6. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Companion Diagnostic Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product and Services
9.3.1.2.2. By Technology
9.3.1.2.3. By Disease Indication
9.3.1.2.4. By Application
9.3.1.2.5. By End User
9.3.2. Argentina Companion Diagnostic Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product and Services
9.3.2.2.2. By Technology
9.3.2.2.3. By Disease Indication
9.3.2.2.4. By Application
9.3.2.2.5. By End User
9.3.3. Colombia Companion Diagnostic Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product and Services
9.3.3.2.2. By Technology
9.3.3.2.3. By Disease Indication
9.3.3.2.4. By Application
9.3.3.2.5. By End User
10. Middle East and Africa Companion Diagnostic Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product and Services
10.2.2. By Technology
10.2.3. By Disease Indication
10.2.4. By Application
10.2.5. By End User
10.2.6. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Companion Diagnostic Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product and Services
10.3.1.2.2. By Technology
10.3.1.2.3. By Disease Indication
10.3.1.2.4. By Application
10.3.1.2.5. By End User
10.3.2. Saudi Arabia Companion Diagnostic Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product and Services
10.3.2.2.2. By Technology
10.3.2.2.3. By Disease Indication
10.3.2.2.4. By Application
10.3.2.2.5. By End User
10.3.3. UAE Companion Diagnostic Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product and Services
10.3.3.2.2. By Technology
10.3.3.2.3. By Disease Indication
10.3.3.2.4. By Application
10.3.3.2.5. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Global Companion Diagnostic Market: SWOT Analysis
